Goldman Sachs
TYRA icon

Goldman Sachs’s Tyra Biosciences TYRA Stock Holding History

Goldman Sachs’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8M Sell
463,477
-86,857
-16% -$2.87M ﹤0.01% 2921
2026
Q1 		$21.1M Buy
550,334
+367,947
+202% +$11.9M ﹤0.01% 2385
2025
Q4 		$4.79M Buy
182,387
+82,237
+82% +$1.51M ﹤0.01% 3784
2025
Q3 		$1.4M Sell
100,150
-5,445
-5% -$62.1K ﹤0.01% 4791
2025
Q2 		$1.01M Buy
105,595
+27,589
+35% +$262K ﹤0.01% 4696
2025
Q1 		$725K Buy
78,006
+13,896
+22% +$180K ﹤0.01% 4936
2024
Q4 		$891K Sell
64,110
-24,971
-28% -$453K ﹤0.01% 4898
2024
Q3 		$2.09M Sell
89,081
-25,793
-22% -$541K ﹤0.01% 4119
2024
Q2 		$1.84M Buy
114,874
+100,797
+716% +$1.74M ﹤0.01% 3982
2024
Q1 		$231K Buy
+14,077
New +$231K ﹤0.01% 5070
2021
Q4 		– Sell
-207,283
Closed -$3.65M – 6713
2021
Q3 		$3.65M Buy
+207,283
New +$3.96M ﹤0.01% 3621

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Goldman Sachs's TYRA Position: Q2 2026 in Review

Goldman Sachs reduced its Tyra Biosciences (TYRA) stake by 16% in Q2 2026, selling an estimated $2.87M and leaving 463,477 shares worth $14.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2921.

Goldman Sachs first reported a position in TYRA in Q3 2021 and has held it in 11 quarters since. The position peaked at $21.1M in Q1 2026. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Goldman Sachs held 463,477 shares of Tyra Biosciences worth $14.8M as of Q2 2026.
  • Goldman Sachs sold 86,857 Tyra Biosciences shares in Q2 2026, an estimated $2.87M.
  • Tyra Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2921 holding.
  • Goldman Sachs first reported a position in Tyra Biosciences in Q3 2021 and has held it in 11 quarters since.
  • Goldman Sachs's Tyra Biosciences position peaked at $21.1M in Q1 2026.
  • 168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.